Genmab A/S (CPH:GMAB)
Denmark · Delayed Price · Currency is DKK 1,611.00
+27.50 (1.74%)
Jun 8, 2026, 4:59 PM CET
Genmab Stock Forecast
Stock Price Forecast
According to 17 analysts polled by S&P Global, Genmab stock has a consensus rating of "Buy" and an average price target of kr 2,313. The average 1-year stock price forecast is 43.58% higher than the current stock price, while the lowest is kr 1,400 (-13.10%) and the highest is kr 3,000 (+86.22%).
Price Target: kr 2,313 (+43.58%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Genmab stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 8 | 9 | 10 | 11 | 11 |
| Buy | 2 | 2 | 1 | 2 | 2 | 2 |
| Hold | 5 | 5 | 5 | 3 | 3 | 3 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 15 | 16 | 16 | 16 | 17 | 17 |
Financial Forecast
Revenue This Year
4.37B
from 3.72B
Increased by 17.45%
Revenue Next Year
5.12B
from 4.37B
Increased by 17.24%
EPS This Year
11.64
from 17.72
Decreased by -34.30%
EPS Next Year
16.72
from 11.64
Increased by 43.63%
EPS and Forward PE are based on non-GAAP adjusted numbers.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 4.7B | ||
| Avg | 4.4B | ||
| Low | 4.2B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 25.4% | ||
| Avg | 17.4% | ||
| Low | 13.6% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | ||
| Avg | 11.64 | ||
| Low | - |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | ||
| Avg | -34.3% | ||
| Low | - |